Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of GHB04L1 H5N1 vaccine in healthy adults
NCT03745274Phase 1Completed
- Sponsor
- AVIR Green Hills Biotechnology AG
- Start
- Dec 2008
- Primary completion
- May 2009
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Avian influenza H5N1 (H5N1) comparing GHB04L1 with Placebo (2 arms). Primary endpoint: Occurrence of adverse events at 8 weeks. Started Dec 2008; status: completed.
02
Drugs
GHB04L1
03
Conditions
Avian influenza H5N1 (H5N1)
Beyond the preview
Go deeper on NCT03745274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03745274.